References
- Lyseng-Williamson KA. Certolizumab pegol administration devices: a profile of their use and usability. Drugs Ther Perspect. 2017;33(11):515–522.
- Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology. 2014;53(8):1377–1385.
- Cimzia®. (Certolizumab Pegol) 200 Mg/Ml Injection [Australian Prescribing Information]. Malvern: UCB Pharma; 2019.
- Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumtol. 2015;10(5):345–356.
- van den Bemt BJ, Gettings L, Domańska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Delivery. 2019;26(1):384–392.
- Bailey K, Mountian I, Bruggraber R, Sunderland K, Tilt N, Szegvari B. Patient Satisfaction with CIMZIA® (Certolizumab Pegol) AutoClicks® in the UK. Adv Ther. 2020;37(4):1522–1535.
- Domańska B, Stumpp O, Poon S, Oray S, Mountian I, Pichon C. Using patient feedback to optimize the design of a certolizumab pegol electromechanical self-injection device: insights from human factors studies. Adv Ther. 2018;35(1):100–115.
- Domańska B, VanLunen B, Peterson L, Mountian I, Schiff M. Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis. Expert Opin Drug Deliv. 2017;14(1):15–22.
- Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9(1):2.
- Schiff M, Saunderson S, Mountian I, Hartley P. Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment. Rheumatol Ther. 2017;4(2):445–463.
- Maniadakis N, Toth E, Schiff M, et al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences. Adv Ther. 2018;35(9):1333–1355.